-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that the new drug marketing application for the envitrazumab injection developed by the group has been accepted by the China Drug Administration. This product is declared as a biological product class 1 new drug for therapeutic use. Its indication is unresectable or metastatic HER2 positive adult breast cancer that has been treated with one or more anti-HER2 drugs in the past.

Zhitongcaijing·07/17/2026 08:57:04
Listen to the news
According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that the new drug marketing application for the envitrazumab injection developed by the group has been accepted by the China Drug Administration. This product is declared as a biological product class 1 new drug for therapeutic use. Its indication is unresectable or metastatic HER2 positive adult breast cancer that has been treated with one or more anti-HER2 drugs in the past.